Millennium Pharmaceuticals, Inc. (MLNM)

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Millennium Pharmaceuticals, Inc. (MLNM)

An SI Board Since February 1997

Posts	SubjectMarks	Bans	Symbol
3044	135	0	MLNM

Emcee: icanpickem	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
2769	Merrill: Interim IFM phase III data consistent with phase II Preliminary interi	tom pope	-	12/11/2006
2768	VELCADE(R) (Bortezomib) for Injection Combination Shows High Complete and Near C	Icebrg	-	12/10/2006
2767	Why ? >>MCL is a relatively uncommon and aggressive form of non-Hodgkin&#	nigel bates	-	12/9/2006
2766	I am amazed that FDA grants approval based on phase II data only.	idos	-	12/9/2006
2765	I'll expect a full report from Erik on each pres'n. :-) ++++++++++++++	Ian@SI	-	12/8/2006
2764	FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Ho	Icebrg	-	12/8/2006
2763	Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) i	Icebrg	-	12/8/2006
2762	And that brings up a competitor I hadn't seen before, Proteolix, in PI with	tuck	-	12/6/2006
2761	Velcade reference in Medscape CME on MCL medscape.com	Ian@SI	-	12/6/2006
2760	Thanks, Jason, You keep following us around and giving us information we want	tuck	-	12/3/2006
2759	<i>The results for combining RAD001 with Rituximab are not included in the	tnsaf	-	12/3/2006
2758	[RAD001 (mTOR inhibitor) and Velcade versus mantle cell lymphoma>> Leukemi	tuck	-	12/2/2006
2757	Millennium Initiates Phase II Trial to Evaluate MLN3897 in Rheumatoid Arthritis	Icebrg	-	11/28/2006
2756	Bortezomib and Thalidomide May Benefit Elderly with Multiple Myeloma NEW YORK N	Icebrg	-	11/27/2006
2755	Bortezomib and dexamethasone in previously untreated multiple myeloma associated	Icebrg	-	11/27/2006
2754	Anticoagulant Reduces Major Bleeds in Acute Coronary Syndromes By Judith Groch,	Icebrg	-	11/23/2006
2753	[HIF-1alpha determines sensitivity of endothelial cells to Bortezomib] >>	tuck	-	11/19/2006
2752	Millennium Closes Sale of $250.0 Million in Convertible Senior Notes Wednesday N	Icebrg	-	11/15/2006
2751	Millennium Prices $225.0 Million in Convertible Senior Notes Thursday November 9	Icebrg	-	11/10/2006
2750	Cambridge Antibody Technology (CAT) said today that it is expanding its operatio	Icebrg	-	11/7/2006
2749	Item 1.01 Entry into a Material Definitive Agreement. [Some autumn cleaning goi	Icebrg	-	11/3/2006
2748	Stock options - from yesterday's 10-Q During the second quarter of 2006, we	Icebrg	-	11/1/2006
2747	In their Q3 report today, Kosan said that: Tanespimycin (KOS-953), our first-ge	Icebrg	-	10/26/2006
2746	Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(	Icebrg	-	10/26/2006
2745	UK's NICE rejects funding of Velcade - news.bbc.co.uk	nigel bates	-	10/21/2006

Go to reply# or date (mm/dd/yy):